Created at	Source	Raw Value	Validated value
May 31, 2021, 12:32 a.m.	usa	Preliminary safety and efficacy evaluation of N-803;Preliminary safety and efficacy evaluation of N-803 by adverse event (AE) incidence;Preliminary safety and efficacy evaluation of N-803 by subject clinical status using a the 7-point ordinal scale.	Preliminary safety and efficacy evaluation of N-803;Preliminary safety and efficacy evaluation of N-803 by adverse event (AE) incidence;Preliminary safety and efficacy evaluation of N-803 by subject clinical status using a the 7-point ordinal scale.
Oct. 26, 2020, 11:31 p.m.	usa	Preliminary safety and efficacy evaluation of N-803 by changes in lymphocyte counts;Preliminary safety and efficacy evaluation of N-803 by subject clinical status using a the 7-point ordinal scale.;Preliminary safety and efficacy evaluation of N-803 by adverse event (AE) incidence	Preliminary safety and efficacy evaluation of N-803 by changes in lymphocyte counts;Preliminary safety and efficacy evaluation of N-803 by subject clinical status using a the 7-point ordinal scale.;Preliminary safety and efficacy evaluation of N-803 by adverse event (AE) incidence